Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


The Study on the Esketamine in the Treatment of Postherpetic Neuralgia


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04664530

Organisation Name: Second Affiliated Hospital, School of Medicine, Zhejiang University

Overal Status: Recruiting

Start Date: November 25, 2020

Last Update: December 11, 2020

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Brief Summary: Herpes zoster (HZ) is an acute herpetic skin disease caused by the reactivation of the varicella-zoster virus (VZV) latent in the sensory ganglia. Postherpetic neuralgia (PHN) often occurs after herpes zoster heals and persists for a long time. At present, clinically anticonvulsants (such as gabapentin, pregabalin) and antidepressants (such as amitriptyline) are clinically first-line drugs for the treatment of PHN, which are not usually effective to treat PHN well, as well as to alleviate patients' bad mental symptoms. Esketamine, as a well-known N-methyl-D-aspartate receptor inhibitor, has both analgesic and antidepressant effects with extremely few incidence of respiratory depression, delirium, hallucinations, nausea and vomiting. Therefore, we hypothesize that esketamine could relieve PHN and Anxiety and depression-like symptoms symptoms in patients with PHN. This study intended to compare the efficacy of pregabalin, amitriptyline combined with esketamine therapy and pregabalin combined with amitriptyline therapy for alleviating PHN, and to further explore the feasibility and safety of esketamine in the treatment of PHN as well as underlying the mechanism of esketamine on the PHN.

Conditions:
  • Postherpetic Neuralgia
  • Esketamine


Total execution time in seconds: 0.20002293586731